Company Overview
About Areteia Therapeutics
Areteia Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral treatments for eosinophil-driven diseases, particularly severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). The company was formerly known as TPI Therapeutics and rebranded as Areteia upon securing significant venture financing. Its lead compound, dexpramipexole, is a small molecule that selectively inhibits eosinophil maturation in the bone marrow — reducing circulating eosinophil levels by 75-90% without the immunosuppressive effects that can accompany broad anti-inflammatory drugs.
Business Model & Competitive Advantage
Areteia raised $215 million in a Series B financing round in 2023, led by OrbiMed Advisors, with participation from Atlas Venture, EQT Life Sciences, and other healthcare-focused investors. The company is conducting the Phase 3 EXHALE trial of dexpramipexole in patients with uncontrolled severe eosinophilic asthma, targeting patients who do not adequately respond to existing inhaled corticosteroids. Approximately 300,000-500,000 patients in the United States are estimated to have severe eosinophilic asthma.
Competitive Landscape 2025–2026
Dexpramipexole's potential market position is significant: if approved, it would be the first oral eosinophil-depleting therapy — an alternative to injectable biologic therapies such as mepolizumab (Nucala), benralizumab (Fasenra), and dupilumab (Dupixent). The oral route of administration is a meaningful clinical and commercial differentiator, as many patients prefer oral medications over self-injection or infusion. Areteia is also exploring dexpramipexole in other eosinophilic conditions beyond asthma.
Key Differentiators
Emerging Innovator
Areteia Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Areteia Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Areteia Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Areteia Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Areteia Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →